Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00UZR
|
|||
| Former ID |
DCL000365
|
|||
| Drug Name |
Palbociclib
|
|||
| Synonyms |
571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Approved | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2], [3] | ||
| Schizophrenia [ICD-11: 6A20] | Terminated | [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Onyx Pharmaceuticals; Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H29N7O2
|
|||
| Canonical SMILES |
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
|
|||
| InChI |
1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
|
|||
| InChIKey |
AHJRHEGDXFFMBM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 571190-30-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8035907, 11062094, 11538604, 12015755, 14808444, 17137183, 39302900, 46394060, 57361299, 78833389, 99436913, 103461613, 103905660, 103905661, 113915142, 121280258, 124360805, 124757012, 125164718, 126580155, 126671645, 126737419, 131480762, 134339015, 134339302, 134339471, 134964422, 135262045, 135686212, 135686213, 135686228, 135686229, 136367313, 136367838, 136920362, 137184856, 137275973, 141483504, 143498887, 144116345, 152240013, 152258827, 152344089, 160647678, 162202562, 164045126, 172232465, 172919351, 177748911, 178103952
|
|||
| ChEBI ID |
CHEBI:85993
|
|||
| ADReCS Drug ID | BADD_D01654 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 | |||
| REF 2 | ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.